187 related articles for article (PubMed ID: 16406098)
1. Pathogenicity and immunogenicity in mice of vaccinia viruses mutated in the viral envelope proteins A33R and B5R.
Gurt I; Abdalrhman I; Katz E
Antiviral Res; 2006 Mar; 69(3):158-64. PubMed ID: 16406098
[TBL] [Abstract][Full Text] [Related]
2. The vaccinia virus 42-kDa envelope protein is required for the envelopment and egress of extracellular virus and for virus virulence.
Engelstad M; Smith GL
Virology; 1993 Jun; 194(2):627-37. PubMed ID: 8503178
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing and protective antibodies directed against vaccinia virus envelope antigens.
Galmiche MC; Goenaga J; Wittek R; Rindisbacher L
Virology; 1999 Feb; 254(1):71-80. PubMed ID: 9927575
[TBL] [Abstract][Full Text] [Related]
4. Differential efficacy of vaccinia virus envelope proteins administered by DNA immunisation in protection of BALB/c mice from a lethal intranasal poxvirus challenge.
Pulford DJ; Gates A; Bridge SH; Robinson JH; Ulaeto D
Vaccine; 2004 Sep; 22(25-26):3358-66. PubMed ID: 15308360
[TBL] [Abstract][Full Text] [Related]
5. Immunization with a single extracellular enveloped virus protein produced in bacteria provides partial protection from a lethal orthopoxvirus infection in a natural host.
Fang M; Cheng H; Dai Z; Bu Z; Sigal LJ
Virology; 2006 Feb; 345(1):231-43. PubMed ID: 16256161
[TBL] [Abstract][Full Text] [Related]
6. Protection induced in mice against a lethal orthopox virus by the Lister strain of vaccinia virus and modified vaccinia virus Ankara (MVA).
Abdalrhman I; Gurt I; Katz E
Vaccine; 2006 May; 24(19):4152-60. PubMed ID: 16603280
[TBL] [Abstract][Full Text] [Related]
7. The vaccinia virus A38L gene product is a 33-kDa integral membrane glycoprotein.
Parkinson JE; Sanderson CM; Smith GL
Virology; 1995 Dec; 214(1):177-88. PubMed ID: 8525613
[TBL] [Abstract][Full Text] [Related]
8. Attenuation of B5R mutants of rabbitpox virus in vivo is related to impaired growth and not an enhanced host inflammatory response.
Stern RJ; Thompson JP; Moyer RW
Virology; 1997 Jun; 233(1):118-29. PubMed ID: 9201221
[TBL] [Abstract][Full Text] [Related]
9. Vaccination of BALB/c mice with Escherichia coli-expressed vaccinia virus proteins A27L, B5R, and D8L protects mice from lethal vaccinia virus challenge.
Berhanu A; Wilson RL; Kirkwood-Watts DL; King DS; Warren TK; Lund SA; Brown LL; Krupkin AK; Vandermay E; Weimers W; Honeychurch KM; Grosenbach DW; Jones KF; Hruby DE
J Virol; 2008 Apr; 82(7):3517-29. PubMed ID: 18199639
[TBL] [Abstract][Full Text] [Related]
10. DNA vaccination with vaccinia virus L1R and A33R genes protects mice against a lethal poxvirus challenge.
Hooper JW; Custer DM; Schmaljohn CS; Schmaljohn AL
Virology; 2000 Jan; 266(2):329-39. PubMed ID: 10639319
[TBL] [Abstract][Full Text] [Related]
11. The N-terminal domain of the vaccinia virus E3L-protein is required for neurovirulence, but not induction of a protective immune response.
Brandt T; Heck MC; Vijaysri S; Jentarra GM; Cameron JM; Jacobs BL
Virology; 2005 Mar; 333(2):263-70. PubMed ID: 15721360
[TBL] [Abstract][Full Text] [Related]
12. Antibodies against the extracellular enveloped virus B5R protein are mainly responsible for the EEV neutralizing capacity of vaccinia immune globulin.
Bell E; Shamim M; Whitbeck JC; Sfyroera G; Lambris JD; Isaacs SN
Virology; 2004 Aug; 325(2):425-31. PubMed ID: 15246280
[TBL] [Abstract][Full Text] [Related]
13. Mutations in the vaccinia virus A33R and B5R envelope proteins that enhance release of extracellular virions and eliminate formation of actin-containing microvilli without preventing tyrosine phosphorylation of the A36R protein.
Katz E; Ward BM; Weisberg AS; Moss B
J Virol; 2003 Nov; 77(22):12266-75. PubMed ID: 14581563
[TBL] [Abstract][Full Text] [Related]
14. Targeting the vaccinia virus L1 protein to the cell surface enhances production of neutralizing antibodies.
Golden JW; Josleyn MD; Hooper JW
Vaccine; 2008 Jun; 26(27-28):3507-15. PubMed ID: 18485547
[TBL] [Abstract][Full Text] [Related]
15. Microarray assay for evaluation of the genetic stability of modified vaccinia virus Ankara B5R gene.
Laassri M; Meseda CA; Williams O; Merchlinsky M; Weir JP; Chumakov K
J Med Virol; 2007 Jun; 79(6):791-802. PubMed ID: 17457926
[TBL] [Abstract][Full Text] [Related]
16. Administration of vaccinia virus to mice may cause contact or bedding sentinel mice to test positive for orthopoxvirus antibodies: case report and follow-up investigation.
Gaertner DJ; Batchelder M; Herbst LH; Kaufman HL
Comp Med; 2003 Feb; 53(1):85-8. PubMed ID: 12625512
[TBL] [Abstract][Full Text] [Related]
17. Parainfluenza virus 5-based vaccine vectors expressing vaccinia virus (VACV) antigens provide long-term protection in mice from lethal intranasal VACV challenge.
Clark KM; Johnson JB; Kock ND; Mizel SB; Parks GD
Virology; 2011 Oct; 419(2):97-106. PubMed ID: 21885079
[TBL] [Abstract][Full Text] [Related]
18. Pathogeneses of respiratory infections with virulent and attenuated vaccinia viruses.
Hayasaka D; Ennis FA; Terajima M
Virol J; 2007 Feb; 4():22. PubMed ID: 17326843
[TBL] [Abstract][Full Text] [Related]
19. Differential antigen requirements for protection against systemic and intranasal vaccinia virus challenges in mice.
Kaufman DR; Goudsmit J; Holterman L; Ewald BA; Denholtz M; Devoy C; Giri A; Grandpre LE; Heraud JM; Franchini G; Seaman MS; Havenga MJ; Barouch DH
J Virol; 2008 Jul; 82(14):6829-37. PubMed ID: 18448519
[TBL] [Abstract][Full Text] [Related]
20. In vitro human CD4+ T cell response to the vaccinia protective antigens B5R and A33R.
Sirven P; Castelli FA; Probst A; Szely N; Maillere B
Mol Immunol; 2009 Apr; 46(7):1481-7. PubMed ID: 19193441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
